Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasquinimod in Myelofibrosis
NCT06327100Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2024
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tasquinimod in myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2024; status: recruiting.
02
Drugs
tasquinimod
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06327100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06327100.